FirstString Research

FirstString Research is a privately-held clinical-stage biotechnology company, which was founded based on pioneering research from the Medical University of South Carolina characterizing the therapeutic role of connexin-based protein signalling. The company's lead drug candidate, Granexin® gel (aCT-1), is a novel, proprietary peptide mimetic of the... C-terminus of connexin43, which has been shown to play a fundamental role in processes that are critical to wound healing. Granexin® gel has demonstrated positive proof-of-concept efficacy and benign safety in three placebo-controlled, randomized, double-blinded clinical trials and is poised to enter Phase 3 development for the treatment of diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The market for DFUs alone in the United States and major European Union economies is estimated to reach $1.6 billion in 2017, according to GlobalData. FirstString Research is headquartered in Charleston, South Carolina.Read More